A liquid biopsy is a test that analyzes genetic material or cellular components circulating in body fluids — most commonly blood — to detect, characterize, or monitor disease. The term is most closely associated with cancer diagnostics, where it has emerged as a powerful complement and, in certain contexts, an alternative to surgical tissue biopsy. But the applications extend beyond oncology: liquid biopsy techniques are used in prenatal testing, transplant monitoring, and infectious disease surveillance, and researchers are actively investigating their utility in neurology, autoimmune disease, and cardiovascular medicine.
The defining advantage is what the name implies: liquids rather than tissues. Drawing blood or collecting urine is fundamentally different from cutting into a patient to extract a tissue specimen. That difference in invasiveness has clinical consequences that extend well beyond patient comfort — it shapes what tests can be repeated, how often, and at what cost.
What Liquid Biopsies Detect
The human bloodstream carries a continuous stream of biological material shed by cells throughout the body. In healthy individuals, this material is largely unremarkable. In the presence of disease — particularly cancer — specific components of that circulating material change in ways that are detectable and clinically meaningful. Liquid biopsies are designed to capture and analyze those signals.
Three classes of biomarker are central to current liquid biopsy applications:
| Analyte | Biological Source | Abundance in Early Disease | Circulation Stability | FDA-Approved Applications | MKA Strategic Implication |
|---|---|---|---|---|---|
| ctDNA | DNA fragments shed by apoptotic/necrotic tumor cells | Low in early-stage; moderate-high in advanced disease | Moderate — susceptible to nuclease degradation; stabilizing tubes required | EGFR/NSCLC, BRCA/ovarian & prostate, RAS/colorectal, PIK3CA/breast, comprehensive profiling panels | ctDNA is the commercial and regulatory anchor for liquid biopsy. The majority of payer coverage determinations, FDA-approved CDx, and clinical utility evidence are built on ctDNA. Any new liquid biopsy program should define its position relative to ctDNA first — either within the ctDNA space (differentiated by cancer type or application) or explicitly replacing it with a superior analyte for a specific use case. |
| CTCs | Intact cancer cells shed from primary tumor into circulation | Very low in early disease; higher in metastatic disease | Good — whole cells are more stable than cell-free DNA if captured rapidly | CellSearch (metastatic breast, colorectal, prostate) — prognostic, not CDx; no FDA-approved CDx applications | CTCs remain clinically validated for prognosis but have not translated into approved CDx applications despite decades of investigation. The low abundance in early-stage disease is a structural limitation for early detection programs. CTC platforms are more likely to contribute as complementary tools within multi-analyte workflows than as standalone CDx anchors. |
| Exosomes | Membrane-enclosed vesicles secreted by all cells, including tumor cells; carry RNA, DNA, and protein cargo | High — shed abundantly even in early-stage disease | High — lipid membrane protects cargo from nuclease degradation in circulation | Growing number of FDA-cleared IVD products incorporating exosome technology (as of late 2024); active CDx clinical trials; no broadly approved CDx indication yet | Exosomes offer the most differentiated technical profile of the three analyte classes — early-stage abundance and cargo stability are genuine advantages over ctDNA. The barrier to clinical adoption is not the biology; it is the absence of standardized isolation methods and the early stage of the reimbursement evidence base. The companies building that evidence base now are defining the category. |
Clinical application data sourced from FDA IVD clearance database, published liquid biopsy literature, and Guardant Health/Foundation Medicine public regulatory submissions. Strategic implications reflect MKA Insights analytical framework.
Circulating Tumor DNA (ctDNA)
When tumor cells die, they release fragments of their DNA into the bloodstream. This circulating tumor DNA carries the same genetic alterations — mutations, copy number changes, fusions — as the tumor of origin. Detecting and sequencing ctDNA makes it possible to characterize the molecular profile of a tumor from a blood sample, without physical access to the tumor itself.
ctDNA is the most extensively validated liquid biopsy analyte. The first FDA-approved liquid biopsy test — Roche’s cobas EGFR Mutation Test — was cleared in 2016 to detect EGFR mutations in non-small cell lung cancer patients who could not provide adequate tissue for testing. Since then, the number of FDA-approved ctDNA-based tests has expanded substantially, including comprehensive genomic profiling panels from Guardant Health and Foundation Medicine that can interrogate hundreds of cancer-relevant genes from a single blood draw.
The sensitivity of ctDNA detection depends on the tumor’s stage and its rate of DNA shedding. Late-stage tumors tend to shed more ctDNA and are therefore easier to detect. Early-stage tumors shed far less, which is the central technical challenge for ctDNA-based early detection tests.
Circulating Tumor Cells (CTCs)
Circulating tumor cells are intact cancer cells that have broken free from the primary tumor and entered the bloodstream. Unlike ctDNA, which consists of cell-free DNA fragments, CTCs are whole cells that carry not just genetic information but also protein expression profiles and cellular architecture that can be analyzed.
CTCs were the first liquid biopsy analyte studied systematically, and the FDA cleared the first CTC-based test — Veridex’s CellSearch system — in 2004 for use in metastatic breast, colorectal, and prostate cancers. However, CTCs are present at very low abundance in circulation, particularly in early-stage disease, which limits their utility for early detection. At later stages, CTC counts correlate with prognosis and can provide prognostic information about treatment response.
Exosomes and Cell-Free RNA
Exosomes are nanoscale vesicles secreted by all cell types, including tumor cells. They carry RNA, DNA, and protein cargo from their cell of origin, and because they are physically protected by a lipid membrane, their cargo is more stable in circulation than cell-free DNA. Tumor-derived exosomes can be captured using antibodies targeting tumor-associated surface proteins, allowing enrichment of cancer-specific material from a blood sample.
Exosome-based diagnostics represent an active frontier. Their abundance in early-stage disease — unlike CTCs, which are often sparse — and the richness of their cargo make them attractive targets for tests designed to detect cancer before symptoms appear. Several exosome-based assays are in clinical validation, and a growing number of in vitro diagnostic products incorporating exosome technologies have received FDA clearance as of late 2024.
Clinical Applications
Early Detection and Screening
Multi-cancer early detection (MCED) tests use ctDNA and other circulating signals to look for cancer across dozens of tumor types simultaneously from a single blood draw. Several MCED tests are in late-stage clinical trials or available through commercial laboratory channels. The clinical science is maturing, and guideline bodies are beginning to assess the evidence for inclusion in screening recommendations — a process that will take years but is directionally positive.
The fundamental challenge for early detection liquid biopsies is sensitivity: early-stage tumors shed very little ctDNA, making detection technically demanding. The performance of current MCED tests varies significantly by cancer type, stage, and tumor location, and the clinical evidence for whether earlier detection leads to better outcomes — the clinical utility bar payers and guideline bodies require — is still accumulating.
Treatment Selection and Companion Diagnostics
For patients with advanced cancer, ctDNA-based tests are used to identify actionable mutations that guide therapy selection. In some cases — particularly when tissue is difficult to obtain or when the patient has widely metastatic disease — a liquid biopsy may be the primary source of molecular profiling information. In other cases, liquid biopsy serves as a complement to tissue biopsy, capturing mutations in metastatic sites that the tissue sample missed.
FDA-approved companion diagnostics based on liquid biopsy include ctDNA tests for EGFR mutations in non-small cell lung cancer, BRCA mutations in ovarian and prostate cancer, and RAS mutations in colorectal cancer. The list of approved liquid biopsy companion diagnostics is expanding as the evidence base grows and pharmaceutical developers incorporate liquid biopsy into their trial designs.
Monitoring Treatment Response and Detecting Resistance
One of the most clinically valuable applications of liquid biopsy is longitudinal monitoring: repeating the test at intervals to track whether ctDNA levels are rising, falling, or holding steady. A falling ctDNA level after treatment initiation is generally a favorable sign. A rising level can signal that the tumor is not responding, or that resistance has emerged — often before these changes are visible on imaging.
Detecting resistance mutations early creates a clinical decision window. When a resistance mutation is identified in ctDNA before a patient’s imaging shows progression, the oncologist has time to consider alternative therapies before the patient’s clinical condition deteriorates. Several liquid biopsy assays are specifically designed and approved for resistance monitoring in targeted cancer therapies.
Minimal Residual Disease Detection
After treatment with curative intent, liquid biopsy can be used to detect minimal residual disease (MRD) — trace amounts of ctDNA that signal the presence of cancer that has survived treatment, even when imaging shows no detectable tumor. MRD-positive status after surgery or chemotherapy is associated with higher risk of recurrence, and liquid biopsy-based MRD tests are being studied as tools to guide decisions about adjuvant therapy.
Non-Oncology Applications
Liquid biopsy techniques extend well beyond cancer. Non-invasive prenatal testing (NIPT) uses cell-free fetal DNA in maternal blood to screen for chromosomal abnormalities, and is now a standard of care component of prenatal screening in many health systems. In organ transplant monitoring, donor-derived cell-free DNA — DNA from the transplanted organ circulating in the recipient’s blood — serves as a non-invasive marker of graft injury and rejection. Several NIPT and transplant monitoring tests have received FDA clearance. Liquid biopsy methods are also being explored in neurological disease, where proteins and nucleic acids in cerebrospinal fluid or blood may serve as early biomarkers for conditions like Alzheimer’s disease and Parkinson’s disease.
Technical Underpinnings
The analytical performance of liquid biopsy tests depends on the sensitivity and specificity of the underlying detection methods. Next-generation sequencing (NGS) platforms enable the sequencing of millions of DNA fragments from a single sample, making it possible to detect rare mutant alleles present at very low frequency against a background of normal cell-free DNA. Digital PCR methods provide highly precise quantification of specific mutations. Error-correction algorithms and unique molecular identifiers are used to distinguish true tumor-derived variants from sequencing artifacts — a critical distinction when target signals are present at fractions of a percent.
The quality of a liquid biopsy result depends on the entire pre-analytical workflow: how blood is collected (specific tube types are required to stabilize cell-free DNA), how rapidly samples are processed, and how reliably cell-free DNA is extracted. Standardization of these pre-analytical steps is an active area of work, with implications for both clinical laboratory operations and the comparability of liquid biopsy results across institutions.
Where Liquid Biopsy Is Headed
The liquid biopsy field is moving toward multi-analyte tests that integrate ctDNA, exosomes, proteins, and other circulating markers into composite signals — a strategy designed to improve sensitivity in early-stage disease and specificity in distinguishing cancer types. AI and machine learning are being applied to interpret the complex, high-dimensional data these tests generate. The combination of highly sensitive detection technologies, multi-platform analyte integration, and AI-assisted interpretation is expected to substantially advance the clinical performance of liquid biopsy over the next decade.
For life sciences companies, the liquid biopsy space offers both opportunity and complexity. The regulatory pathway is navigable but requires careful attention to which analyte class is being used and what clinical claim is being made. The reimbursement environment is evolving: CMS has issued local and national coverage determinations for several ctDNA-based tests, and payer engagement on clinical utility evidence is increasingly active. The tests that will achieve broad clinical adoption are those that can demonstrate not just analytical and clinical validity, but that they change clinical decisions in ways that improve patient outcomes.